leading supplier of cold chain solutions
 
In-Transit FlashLink® Data Manager
    FDA 21 CFR Part 11 Compliant - (Now available: IQ/OQ Protocol for Software Validation)

  Products

 • Data Loggers
 • Temperature
   Recorders

 • Infrared
   Thermometers

 • Probe Thermometers
 • Thermo
   Hygrometers

 • Thermo Labels/Kits/
   Ethylene Repair

 • ISFET pH Meters
 • Ordering Info
 • NEW Dry Ice Logger
 • Pharmaceutical Cold
   Chain Management

 • Press Releases
 Search
 


FDA-regulated companies in pharmaceutical, biotechnology, medical device, blood and other life sciences industries within the GxP industry environments are required to comply with 21 CFR Part 11 for electronic record keeping.
FlashLink Data Manager desktop application is a comprehensive data management tool for use in conjunction with In-Transit FlashLink Data Loggers + our patented Shadow Log Technology.
User-defined alert/reminder messages can be "attached" to each key software function. Drastically reduce human operational error and costly training time.
Company standard operating procedure can be easily defined for each key software function!
Full individual and group audit trails readily available for FDA and internal inspection
Logger data authentication safe-guards against data manipulation / tampering.

Request for more information:
Name:
E-mail:
Phone:
Organization:
Product:
What are the benefits of using FlashLink Data Manager? Compliance is just one of the benefits gained. Implementing electronic signatures and electronic records as specified by 21 CFR Part 11 has many other benefits including:
  • Better Quality Control – Reduce costs associated with product loss
  • Improved Efficiency – Search and find documents in a fraction of the time
  • Risk Avoidance – Be prepared for FDA inspections and minimize human error
  • Faster Time to Market – Reduce the costly time delays associated with lengthy approval cycles
  • Individual user’s software access rights can be customized depending on user's responsibilities and the company SOP.


    Cost of noncompliance
    With the increasing number of 483s and warning letters, the cost of noncompliance continues to be very high. Organizations that are deemed by the FDA as out-of-compliance, or those who incurred consent decrees are spending significant finanical and human resources in remediation. As FDA audits continue, 21 CFR Part 11 compliance should be a top priority, especially in regards to cGxPs.

    We can help...
    Please call 1-800-962-6776 for more information.